Stefan Posse1, 2, Tongsheng Zhang1, Melanie Royce3, Zoneddy Dayao3, Susan Lopez4, Laurel Sillerud5, Stephen Eberhardt6, Lesley Lomo7, Sang-Joon Lee8, Ashwani Rajput9, John Russell9, Linda Casey10, Patrick Bolan11
1Neurology, University of New Mexico, Albuquerque, NM, United States; 2Electrical and Computer Engineering, Physics and Astronomy, University of New Mexico, Albuquerque, NM, United States; 3Medical Oncology, University of New Mexico, Albuquerque, NM, United States; 4Clinical Trials Office, University of New Mexico, Albuquerque, NM, United States; 5Biochemistry, University of New Mexico, Albuquerque, NM, United States; 6Radiology, University of New Mexico, Albuquerque, NM, United States; 7Pathology, University of New Mexico, Albuquerque, NM, United States; 8Internal Medicine, University of New Mexico, Albuquerque, NM, United States; 9Surgery, University of New Mexico, Albuquerque, NM, United States; 10New Mexico Cancer Center, Albuquerque, NM, United States; 11Center for Magnetic Resonance Research, University of Minnesota, Minneapolis, MN, United States
Eleven patients with biopsy-confirmed, infiltrating ductal carcinoma were studied at 3T using 3D lipid suppressed Proton-Echo-Planar-Spectroscopic-Imaging (PEPSI) with a 10 min scan protocol and 1 cc voxel size. Strongly elevated tCho with mean concentrations between 0.3 and 4.1 mmol/kg was measured in 8 of the 11 patients with single and multi-centric enhancing lesions. Decreases in tCho concentration and number of voxels with detectable tCho were measured in 3 patients who underwent neoadjuvant therapy. An increase was measured in one patient. At TE 60 ms an additional resonance was detected that was elevated in enhancing lesions and tentatively assigned to Taurine.